I just posted a press release from Celgene, announcing their 3rd quarter financials for 2011 on my MyelomaNews.com site.

The International Myeloma Foundation (IMF) reports that pomalidomide and carfilzomib “are both moving closer to approval for patients who have relapsed or do not respond to current drugs.” in their summer addition of Myeloma Today.

Two myeloma related industry press releases went out today. 

One of our regular readers, named Linda, forwarded me info about this IMF fundraiser, sponsored by Celgene.  Simply click-on the headline link to reach the site:

Multiple Expressions:  Create a Kite for a Cause.
                                 
Celgene has promised to donate “up to” $25,000 per year through the promotion.  I’m not sure how much is contributed per kite.

Read this detailed recap/tribute to Geraldine Ferraro by Ann Law for Bizmology.com:

I know I promised to share pictures of my Super Bowl Sunday trip to see the new manatee sanctuary.  I will, I will… Pattie has the disc I need to download the pictures.  I will get to that tomorrow.

I just returned from a wonderful mid-day trip with my fellow members of the Friends of the Tampa Bay National Wildlife Refuges to view manatees in the newly acquired Three Springs sanctuary in Crystal River, Florida.

Wednesday I shared a few specifics from Celgene Corporation’s 2010 annual report.  You can read the company’s entire press release by going to Myeloma News.com and clicking on:
CELGENE REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2010 OPERATING AND FINANCIAL RESULTS.

Celgene Corporation, makers of the oral, anti-myeloma chemotherapy agent, Revlimid, announced their 4th quarter and full-year financials this morning.

More news from last month’s ASH.  Here is a University of Michigan press release about the early success of a Revlimid/carfilzomib/dex combo in multiple myeloma patients:

Here is part of the latest press release from Celgene, makers of the oral multiple myeloma chemotherapy drug, Revlimid:

Happy New Year! I wanted to share my multiple myeloma research and drug company “wish list” with my fellow patients and caregivers today.

I just reported some positive news about Revlimid on Sunday, American Society of Clinical Oncology Recognizes Revlimid As One Of The Year’s “Most Notable Advances.” 

The American Society of Clinical Oncology (ASCO) issues an annual report yearly.  Revlimid is prominently mentioned in this years report, published in the Journal of Clinical Oncology, in the “Notable Advances” category.  Here is what the report had to say about Revlimid (lenalidomide):

Celgene shares plummet on Revlimid malignancy data

By Toni Clarke – BOSTON – Mon Dec 6, 2010
BOSTON (Reuters) – Celgene Corp (CELG.O) shares fell more than 9 percent on Monday after data was reported that showed an increase in the risk of secondary malignancies in certain patients taking its blood cancer drug, Revlimid, for extended periods of time…

As a long term (approaching four years) Revlimid user, this Wall Street Journal story I read yesterday obviously concerns me, too:

Potentially good news for smoldering multiple myeloma patients from yesterday’s poster sessions here at ASH:

Thanks, Mike!  Feel good, keep smiling and hold on to your wallet!  Pat

As promised, today I would like to take a look at how a drug like thalidomide, which was first created and distributed over forty years ago, could still be controlled by drug maker Celgene.

Two weeks ago I started an ongoing series, Examining The High Cost Of Celgene’s Multiple Myeloma Drugs.